4DMT Announces Positive Long-Term Data from Phase 1/2 PRISM Clinical Trial in Wet AMD Supporting 4D-150’s Potential as a Backbone Therapy with Consistent and Durable Benefit over Multiple Years

Core Insights - 4D Molecular Therapeutics announced positive interim data from the Phase 1/2 PRISM clinical trial for 4D-150, targeting wet age-related macular degeneration (wet AMD) with potential to transform treatment paradigms [1][10] Patient Cohort Overview - The PRISM trial included various patient cohorts, with a focus on recently diagnosed and severe, recalcitrant disease activity [6] Treatment Efficacy - 4D-150 demonstrated maintained visual acuity and sustained control of retinal anatomy across all cohorts, with a significant reduction in treatment burden through fewer anti-VEGF injections over up to 2 years [3][5] - The Phase 2b subgroup of recently diagnosed patients showed a 92% reduction in supplemental injections at 1.5 years, compared to 77% in the comparator group [11] - The Phase 1/2a cohort maintained a 79% reduction in supplemental injections at 2 years, compared to 69% in the comparator group [11] Safety Profile - 4D-150 was well tolerated, with no new safety concerns or intraocular inflammation findings reported, consistent with previous updates [5][11] - Only 2.8% of patients experienced mild intraocular inflammation within the first 6 months, with no new cases reported thereafter [11] Clinical Trial Progress - Enrollment for the Phase 3 4FRONT-1 trial has exceeded expectations, with over 200 patients randomized to date, and the 4FRONT-2 trial remains on track for completion in H2 2026 [5][10] Market Potential - Wet AMD is a prevalent disease, with over 4 million individuals expected to be affected in major markets within the next five years, highlighting a significant unmet need for effective treatments [14]